Kamada (IL:KMDA)
TASE:KMDA
Want to see IL:KMDA full AI Analyst Report?
KMDA Stock Chart & Stats
2502.00
1.39(5.72%)
At close: 4:00 PM EST
2502.00
1.39(5.72%)
Day’s Range― - ―
52-Week Range1,899.20 - 2,806.07
Previous CloseN/A
Volume698.59K
Average Volume (3M)61.53K
Market Cap
₪1.24B
Enterprise Value397.52M
Total Cash (Recent Filing)₪73.15M
Total Debt (Recent Filing)₪11.64M
Price to Earnings (P/E)21.0
Beta0.72
Next Earnings
Aug 19, 2026EPS Estimate
31.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding57,686,054
10 Day Avg. Volume102,707
30 Day Avg. Volume61,533
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)1.52
Price to Sales (P/S)2.09
P/FCF Ratio24.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₪3,797.06Price Target Upside51.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.44
Revenue Forecast (FY)₪202.22M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthKamada's very low leverage and sizable equity base provide durable financial flexibility: supports ongoing capex for plasma centers, funds dividends and potential M&A, and reduces refinancing risk during cyclical revenue swings, enabling steadier execution of strategic growth plans.
Long-term Commercial ContractsA multi-year Kedrion supply deal with minimums through 2031 gives sustained revenue visibility and production planning certainty. This underpins capacity utilization, reduces commercial volatility, and materially de-risks near-term organic growth assumptions embedded in guidance.
Vertical Integration & Plasma ExpansionOwning FDA-approved plasma centers creates secure raw material sourcing and lowers COGS risk over time. Normal-source plasma sales and planned capacity improve supply resilience, enhance gross margin upside potential and support long-term self-sufficiency for plasma-derived therapeutics.
Bears Say
Cash Flow VolatilityFree cash flow has been inconsistent: TTM FCF covered only ~61% of net income and prior years included negative FCF. This uneven conversion constrains capital allocation flexibility, raises sensitivity to revenue timing, and could pressure dividend sustainability or fund investment without external financing.
Margin PressureA ~5 percentage‑point Y/Y gross margin decline reflects product and geographic mix shifts. If structural mix, pricing or reimbursement trends persist, margin compression would reduce adjusted EBITDA and free cash flow, weakening the company’s ability to fund growth initiatives and sustain dividend targets.
Revenue Variability / SeasonalityDependence on end‑user patterns, partner inventory cadence and outbreak-driven demand creates quarter-to-quarter revenue swings. Such variability complicates capacity planning and forecasting, can magnify cash flow volatility and makes consistent margin expansion harder to achieve over the medium term.
Kamada News
KMDA FAQ
What was Kamada’s price range in the past 12 months?
Kamada lowest stock price was 1899.20 and its highest was 2806.07 in the past 12 months.
What is Kamada’s market cap?
Kamada’s market cap is ₪1.24B.
When is Kamada’s upcoming earnings report date?
Kamada’s upcoming earnings report date is Aug 19, 2026 which is in 61 days.
How were Kamada’s earnings last quarter?
Kamada released its earnings results on May 13, 2026. The company reported 23.87 earnings per share for the quarter, missing the consensus estimate of 32.68 by -8.809.
Is Kamada overvalued?
According to Wall Street analysts Kamada’s price is currently Undervalued.
Does Kamada pay dividends?
Kamada pays a Notavailable dividend of 77 which represents an annual dividend yield of N/A. See more information on Kamada dividends here
What is Kamada’s EPS estimate?
Kamada’s EPS estimate is 31.83.
How many shares outstanding does Kamada have?
Kamada has 57,686,054 shares outstanding.
What happened to Kamada’s price movement after its last earnings report?
Kamada reported an EPS of 23.87 in its last earnings report, missing expectations of 32.68. Following the earnings report the stock price went down -7.347%.
Which hedge fund is a major shareholder of Kamada?
Currently, no hedge funds are holding shares in IL:KMDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kamada Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
₪3,797.06 (51.76% Upside)
₪3,797.06 (51.76% Upside)
Blogger Sentiment
Bullish
IL:KMDA Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.70%
12-Months-Change
Fundamentals
Return on Equity
7.73%
Trailing 12-Months
Asset Growth
2.11%
Trailing 12-Months
Company Description
Kamada
Kamada Ltd. is a biopharmaceutical firm specializing in protein therapies derived from blood plasma. Its operations are divided into two primary areas: developing and marketing its own proprietary products, and distributing a portfolio of third-party pharmaceuticals. Under its proprietary segment, Kamada develops and sells treatments such as KAMRAB/KEDRAB for rabies prevention, CYTOGAM for preventing cytomegalovirus in transplant recipients (including kidney, lung, liver, pancreas, heart, and heart/lung), WINRHO SDF for immune thrombocytopenic purpura (ITP) and to prevent Rh sensitization, HEPAGAM B for post-exposure prophylaxis and to stop hepatitis B recurrence after liver transplants, VARIZIG for post-exposure varicella prophylaxis, and GLASSIA, an intravenous therapy for Alpha-1 Antitrypsin Deficiency (AATD). Additional proprietary offerings include KamRho (D) IM for preventing hemolytic disease in newborns, KamRho (D) IV for immune thrombocytopenic purpura, and an antiserum specifically designed to treat snake bites from Vipera palaestinae and Echis coloratus. Through its distribution arm, Kamada provides a diverse portfolio of pharmaceuticals and medical devices. This includes BRAMITOB for chronic pulmonary infections, FOSTER for asthma management, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, the AEROBIKA OPEP device, RUPAFIN for allergic rhinitis and urticaria, IVIG for various immunodeficiency conditions, VARITECT for chickenpox and herpes zoster, ZUTECTRA and HEPATECT CP for hepatitis B, MEGALOTECT CP for cytomegalovirus, RUCONEST for angioedema attacks, heparin sodium injection for treating and preventing thromboembolic disorders, ALBUMIN for blood plasma, Factor VIII for hemophilia A, and Factor IX for hemophilia B. The distributed range also features IXIARO for Japanese encephalitis, VIVOTIF for Salmonella Typhi, PROCYSBI for nephropathic cystinosis, LAMZEDE for alpha-mannosidosis, and ELIGARD for prostate cancer. Kamada employs a multi-channel commercial strategy, utilizing strategic partners to market its products within the United States and relying on a network of distributors for its international sales. Key strategic alliances include collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, the company's headquarters are located in Rehovot, Israel.
KMDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear operational progress and strategic catalysts—reaffirmed 2026 guidance, FDA approval of a plasma center, expanding commercial and distribution initiatives, growing utilization of key products, and a maintained dividend—with near‑term headwinds including a shipment delay, gross margin compression, and slight cash reduction following the dividend. Management emphasized organic growth drivers and M&A/business development opportunities, and adjusted EBITDA and net income trends were stable to modestly improved, supporting a constructive outlook despite some quarter‑specific challenges.View all IL:KMDA earnings summariesKMDA Stock 12 Month Forecast
Average Price Target
3,797.06
▲(51.76% Upside)